Aim Survival estimates are commonly reported as survival from the first observation, but future survival probability changes based on the survival time already accumulated after therapy, otherwise known as conditional survival (CS). The aim of the study was to describe CS according to different prognostic variables in hepatocellular carcinoma (HCC) patients treated with radiofrequency ablation (RFA). Methods Data on 125 very early/early HCC patients treated with RFA between 1999 and 2007 were analyzed. Actuarial survival estimates were computed by means of Kaplan–Meier method and compared by log–rank test. The 5-year CS was calculated with stratification by several predictors for patients who had already survived up to 5 years from dia...
Sorafenib is the first multikinase inhibitor demonstrating a survival benefit for patients suffering...
Background/ Aims: To evaluate the long-term outcome of surgical and non-surgical local treatments of...
Sorafenib is the first multikinase inhibitor demonstrating a survival benefit for patients suffering...
Conditional survival (CS) provides a prognosis of patients who have already survived several years a...
<p><b>Background</b>: Compared with overall survival, conditional survival is a more relevant measur...
PURPOSE: Conditional survival estimates (CSE) can provide additional useful prognostic information o...
Background: The impact of tumor burden score (TBS) on conditional survival (CS) among patients under...
IMPORTANCE Whereas conventional actuarial overall survival (OS) estimates rely exclusively on static...
Survival analysis belongs to the longitudinal or follow-up epidemiological studies, in which a prede...
Knowing the spontaneous outcome of hepatocellular carcinoma (HCC) is important for designing randomi...
Knowing the spontaneous outcome of hepatocellular carcinoma (HCC) is important for designing randomi...
Background: Radio-frequency ablation (RFA) has been employed in the treatment of Barcelona Clinic Li...
Background: Radio-frequency ablation (RFA) has been employed in the treatment of Barcelona Clinic Li...
Purpose: To clarify the prognostic factors for long-term survival by studying the clinical factors o...
Sorafenib is the first multikinase inhibitor demonstrating a survival benefit for patients suffering...
Sorafenib is the first multikinase inhibitor demonstrating a survival benefit for patients suffering...
Background/ Aims: To evaluate the long-term outcome of surgical and non-surgical local treatments of...
Sorafenib is the first multikinase inhibitor demonstrating a survival benefit for patients suffering...
Conditional survival (CS) provides a prognosis of patients who have already survived several years a...
<p><b>Background</b>: Compared with overall survival, conditional survival is a more relevant measur...
PURPOSE: Conditional survival estimates (CSE) can provide additional useful prognostic information o...
Background: The impact of tumor burden score (TBS) on conditional survival (CS) among patients under...
IMPORTANCE Whereas conventional actuarial overall survival (OS) estimates rely exclusively on static...
Survival analysis belongs to the longitudinal or follow-up epidemiological studies, in which a prede...
Knowing the spontaneous outcome of hepatocellular carcinoma (HCC) is important for designing randomi...
Knowing the spontaneous outcome of hepatocellular carcinoma (HCC) is important for designing randomi...
Background: Radio-frequency ablation (RFA) has been employed in the treatment of Barcelona Clinic Li...
Background: Radio-frequency ablation (RFA) has been employed in the treatment of Barcelona Clinic Li...
Purpose: To clarify the prognostic factors for long-term survival by studying the clinical factors o...
Sorafenib is the first multikinase inhibitor demonstrating a survival benefit for patients suffering...
Sorafenib is the first multikinase inhibitor demonstrating a survival benefit for patients suffering...
Background/ Aims: To evaluate the long-term outcome of surgical and non-surgical local treatments of...
Sorafenib is the first multikinase inhibitor demonstrating a survival benefit for patients suffering...